Jiangsu Hengrui Medicine Co Ltd (600276.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE0000014W7
Jiangsu Hengrui Medicine Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 27.98 bn CNY | 31.43 bn CNY |
| Gross profit | 24.10 bn CNY | 26.67 bn CNY |
| Operating income | 7.49 bn CNY | 8.02 bn CNY |
| EBIT | 6.48 bn CNY | 8.02 bn CNY |
| Net income | 6.34 bn CNY | 7.71 bn CNY |
| Diluted EPS – continuing operations | 1.00 CNY | 1.18 CNY |
Full history since 1997, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
More stocks
- Exelon (EXC)
- Commerzbank (CBK.DE)
- Comfort Systems USA (FIX)
- NEC Corp (6701.T)
- Hangzhou Hikvision Digital Technology Co Ltd (002415.SZ)
- Danone SA (BN.PA)
- Waters Corporation (WAT)
- Astera Labs, Inc. (ALAB)
- Idexx Laboratories (IDXX)
- Ventas (VTR)
- Givaudan SA (GIVN.SW)
- Sun Life Financial Inc (SLF.TO)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.